How do Leqvio (inclisiran), Repatha (evolocumab), and Praluent (alirocumab) compare for additional LDL‑C lowering in patients on maximally tolerated statin therapy?

PCSK9 Inhibitor Comparison: Leqvio vs. Repatha vs. Praluent

For patients on maximally tolerated statin therapy requiring additional LDL-C lowering, PCSK9 monoclonal antibodies (Repatha/evolocumab and Praluent/alirocumab) are preferred as first-line PCSK9 inhibitors due to proven cardiovascular outcomes benefits, while Leqvio (inclisiran) should be reserved for patients with documented poor adherence to injectable therapies or those unable to self-inject. 1

Guideline-Based Recommendations

The 2022 ACC Expert Consensus establishes a clear hierarchy: PCSK9 monoclonal antibodies (mAbs) are the preferred initial PCSK9 inhibitor choice based on demonstrated safety, efficacy, and cardiovascular outcomes benefits in the FOURIER trial (evolocumab) and ODYSSEY Outcomes trial (alirocumab) 1. Inclisiran's cardiovascular outcomes trials (ORION-4 and VICTORION-2P) are not expected to complete until 2026-2027, leaving a critical evidence gap for hard clinical endpoints 1.

When to Consider Each Agent:

PCSK9 mAbs (Repatha or Praluent) - First Choice:

• Proven reduction in cardiovascular events (MI, stroke, cardiovascular death)
• Established safety profile with up to 4 years of data 2
• Appropriate for all patients requiring PCSK9 inhibition 1

Inclisiran (Leqvio) - Alternative Choice:

• Primary indication: Poor adherence to PCSK9 mAbs due to twice-yearly dosing advantage 1
• Patients experiencing adverse effects from both PCSK9 mAbs 1
• Patients unable to self-inject who prefer office-based administration 1

LDL-C Lowering Efficacy: Essentially Equivalent

All three agents achieve robust and comparable LDL-C reductions of approximately 50-60% when added to maximally tolerated statin therapy:

• Praluent (alirocumab): 54-58% reduction at 24 weeks 3
• Repatha (evolocumab): ~60% reduction (referenced in guidelines) 1, 2
• Leqvio (inclisiran): Comparable to PCSK9 mAbs, with network meta-analysis showing no significant difference (MD: -1.93% vs alirocumab, +2.00% vs evolocumab) 4

Recent real-world data confirms no statistically significant differences in LDL-C lowering between the three agents at 180 days 5, 6. One systematic review suggested alirocumab achieved the greatest LDL-C reduction (72.4% at maximum dosing), but this reflects dosing variations rather than inherent superiority 7.

Dosing Considerations

Praluent (alirocumab):

• 75 mg or 150 mg subcutaneous every 2 weeks
• Alternative: 300 mg every 4 weeks
• Dose adjustable based on LDL-C response 3

Repatha (evolocumab):

• 140 mg subcutaneous every 2 weeks
• Alternative: 420 mg monthly

Leqvio (inclisiran):

• 284 mg subcutaneous at baseline, 3 months, then every 6 months
• Key advantage: Twice-yearly dosing may improve long-term adherence 1
• Real-world data shows highest treatment persistence (69.7% vs 56.1% for evolocumab and 50.0% for alirocumab) 5

Safety Profile: All Well-Tolerated

All three agents demonstrate excellent safety profiles with minimal differences:

• Injection site reactions <5%, predominantly mild 2
• No evidence of increased hemorrhagic stroke risk 2
• Safety of very low LDL-C levels (<20 mg/dL) established 2
• No new safety signals in real-world studies 5, 6
• Muscle symptoms and new-onset diabetes rates similar to or lower than standard statin therapy 2

Critical Clinical Decision Points

Choose PCSK9 mAbs (Repatha or Praluent) when:

• Patient is at very high cardiovascular risk requiring proven event reduction
• First-time PCSK9 inhibitor initiation
• Patient can reliably self-inject every 2 weeks
• Cardiovascular outcomes data is prioritized

Choose Inclisiran (Leqvio) when:

• Documented non-adherence to PCSK9 mAbs (most important indication)
• Patient preference for less frequent dosing
• Inability to self-inject (office-based administration preferred)
• Adverse effects from both alirocumab and evolocumab
• LDL-C lowering is primary goal and cardiovascular outcomes data can wait

Important Caveats:

Never combine PCSK9 mAb with inclisiran - no evidence for additive benefit and mechanistically implausible 1. If switching from mAb to inclisiran or vice versa, discontinue one before starting the other.

For patients at very high risk (recent ACS, multiple vascular beds, progressive disease despite therapy), prioritize PCSK9 mAbs given proven cardiovascular event reduction 1, 2. The 2018 ESC/EAS guidance emphasizes that in very high-risk patients with substantially elevated LDL-C, adding a PCSK9 inhibitor can reduce 5-year cardiovascular events, with NNT as low as <30 patients when baseline LDL-C >140 mg/dL 2.

Lipoprotein(a) Considerations

All PCSK9-targeted therapies reduce Lp(a) by approximately 25% with no significant differences between agents 8. This should not drive agent selection, as the magnitude of Lp(a) reduction is equivalent across all options.